Respiratory infections
Michael S Niederman, Antoni Torres, Michael S Niederman, Antoni Torres
Abstract
A new European Respiratory Review series explores respiratory infections https://bit.ly/3A5eN3A
Conflict of interest statement
Conflict of interest: M.S. Niederman has received grants or contracts for research from Merck and Bayer (paid to his institution), and consulting fees from Thermo Fisher, Pfizer, Merck and Dompe. A. Torres reports participation on Advisory Boards or lectures for Pfizer, MSD, Biomerieux, Biotest and Jansen.
References
- Cilloniz C, Luna CM, Hurtado JC, et al. . Respiratory viruses: their importance and lessons learned from COVID-19. Eur Respir Rev 2022; 31: 220051. doi:10.1183/16000617.0051-2022
- Cavallazzi R, Ramirez JA. How and when to manage respiratory infections out of hospital. Eur Respir Rev 2022; 31: 220092. doi:10.1183/16000617.009-2022
- Niederman MS, Torres A. Severe community-acquired pneumonia. Eur Respir Rev 2022; in press [10.1183/16000617.0123-2022].
- Reynolds D, Burnham JP, Vazquez Guillamet C, et al. . The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic. Eur Respir Rev 2022; 31: 220068. doi:10.1183/16000617.0068-2022
- Lamoth F, Calandra T. Pulmonary aspergillosis: diagnosis and treatment. Eur Respir Rev 2022; in press [10.1183/16000617.0114-2022].
- Puerta-Alcalde P, Garcia-Vidal C. Non-Aspergillus mould lung infections. Eur Respir Rev 2022; 31: 220104. doi:10.1183/16000617.0104-2022
- Kumar K, Daley CL, Griffith DE, et al. . Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments. Eur Respir Rev 2022; 31: 210212. doi:10.1183/16000617.0212-2021
- Al-Tawfiq JA, Kim H, Memish ZA, et al. . Parasitic lung diseases. Eur Respir Rev 2022; in press [10.1183/16000617.0093-2022]. doi:10.1183/16000617.0093-2022
Source: PubMed